Scholarlink

<p>Drug-based anti-tumor therapy is evolving from classical cytotoxic chemotherapy to increasingly specific immunotherapies. Unlike monoclonal antibodies, bispecific antibodies (BsAbs) target two different antigens, allowing them to either connect immune effector cells with tumor cells or to block two distinct signaling pathways in tumor cells. Several BsAbs have already been approved for treatment of hematologic malignancies and selected solid tumors. However, the mechanisms of resistance to BsAbs are not yet fully understood, and their side effects remain a&#xa0;major challenge in clinical practice. Furthermore, the optimal sequencing of BsAbs and other anti-tumor therapies, including CAR-T&#xa0;cells, has not been defined. In this review article, we discuss mechanisms of action and resistance, current clinical data, and future developments pertaining to BsAbs in hematologic malignancies and solid tumors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bispezifische Antikörper in der Therapie hämatologischer Neoplasien und solider Tumoren

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月20日

查看全文
  • Xiang Zhou,
  • Johannes M. Waldschmidt,
  • Hermann Einsele

摘要

Drug-based anti-tumor therapy is evolving from classical cytotoxic chemotherapy to increasingly specific immunotherapies. Unlike monoclonal antibodies, bispecific antibodies (BsAbs) target two different antigens, allowing them to either connect immune effector cells with tumor cells or to block two distinct signaling pathways in tumor cells. Several BsAbs have already been approved for treatment of hematologic malignancies and selected solid tumors. However, the mechanisms of resistance to BsAbs are not yet fully understood, and their side effects remain a major challenge in clinical practice. Furthermore, the optimal sequencing of BsAbs and other anti-tumor therapies, including CAR-T cells, has not been defined. In this review article, we discuss mechanisms of action and resistance, current clinical data, and future developments pertaining to BsAbs in hematologic malignancies and solid tumors.